Clinical Trial Update: A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of rindopepimut/GM-CSF in patients with relapsed EGFRvIII-positive glioblastoma has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• rindopepimut/GM-CSF (rindopepimut)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Glioblastoma, Small Cell Glioblastoma | Phase 2 | Status: COMPLETED